This is a non-core endpoint: only basic statistics are computed.
Abnormal findings in secretions and smears from cervix uteri vagina vulva
R18_ABNORMAL_FINDI_SECRE_SMEARS_CERVIX_UTERI_VAGINA_VULVA
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
17691
Check minimum number of events None
17691
Include endpoints None
17691
Remove individuals based on genotype QC
17040
R18_ABNORMAL_FINDI_SECRE_SMEARS_CERVIX_UTERI_VAGINA_VULVA
Control definitions
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
R8[3-9]
Name in latin
Reperta abnormia in speciminibus ex organis genitalibus femininis
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Abnormal findings in secretions and smears from cervix uteri vagina vulva
based on the number of shared cases.
Broader endpoints:
- Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 17040 | 17039 | - |
| Unadjusted prevalence (%) | 4.52 | 8.08 | - |
| Mean age at first event (years) | 40.98 | 40.98 | - |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: R18_ABNORMAL_FINDI_SECRE_SMEARS_CERVIX_UTERI_VAGINA_VULVA – Abnormal findings in secretions and smears from cervix uteri vagina vulva
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Abnormal findings in secretions and smears from cervix uteri vagina vulva
↥Endpoint not on priority list, no data to show.